← Back to Clinical Trials
RecruitingNCT06101693

Biomarkers in Patients With Suspected HFpEF

Trial Parameters

ConditionHeart Failure
SponsorNHS Greater Glasgow and Clyde
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment1,028
SexALL
Min Age18 Years
Max AgeN/A
Start Date2023-02-02
Completion2025-09-29
Interventions
Plasma biomarker levels

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1. alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity 2. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity. 3. novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L 4. the prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L)

Eligibility Criteria

Inclusion Criteria: * Written informed consent * Age ≥ 18 years * NT-proBNP sample taken by primary care physician as part of routine care for suspected heart failure Exclusion Criteria: * Unable to consent to inclusion in study due to significant cognitive impairment * Geographical/ social reasons preventing attending study centre * Unable to complete study assessments * Patients presenting with acute HF or a previous diagnosis of HF

Related Trials